ResMed stock hits 52-week high at 293.1 USD

ResMed (RMD) recently achieved a 52-week high of $293.1, reflecting a 26.9% year-to-date gain and robust financial health, underscored by a 25% dividend growth. For Q4 FY2025, the company reported mixed results, with EPS of $2.55 surpassing the $2.48 forecast but revenue of $1.3 billion falling short of the $1.33 billion anticipation. Despite strong performance metrics, InvestingPro analysis suggests the stock is slightly overvalued at current levels.

Analysis

ResMed Inc. (RMD) has demonstrated significant market strength, reaching a 52-week high of $293.1 on the back of a 26.9% year-to-date gain. This performance is underpinned by robust fundamentals, including a 'GREAT' financial health score, a strong current ratio of 3.44, and a notable 25% increase in its dividend, signaling management's confidence in cash flows. However, the most recent quarterly results for Q4 FY2025 present a mixed picture. While the company surpassed earnings expectations with an EPS of $2.55 against a $2.48 forecast and posted a 23% rise in non-GAAP diluted EPS, it fell short on revenue, reporting $1.3 billion versus an anticipated $1.33 billion. This revenue miss occurred despite a 10% year-over-year increase in group revenue. Compounding this mixed signal, an external analysis suggests the stock is now 'slightly overvalued' at its current price, indicating that the positive performance may be fully reflected in the valuation.

Key Decisions for Investors

• Given the stock is at a 52-week high and flagged as slightly overvalued, investors with substantial gains may consider trimming their positions to capitalize on the recent run-up, especially in light of the Q4 revenue miss.
• Potential investors should exercise caution, as the combination of a valuation premium and a slight top-line miss suggests waiting for a more attractive entry point or clearer signs of revenue re-acceleration before initiating new positions.
• Investors should closely monitor future revenue figures to determine if the Q4 miss was an anomaly or the beginning of a decelerating trend, as sustained top-line growth will be critical to justifying the current valuation.